GxP Applications
Biological drug products must be quality control (QC) tested using robust methods that are appropriately qualified and validated under GMP conditions. The Octet® BLI platform facilitates method development for in-process and lot release testing that can be easily transferred to QC. The ease-of-use and high throughput capacity of Octet® systems allow for enhanced productivity of up to 40x over enzyme-linked immunosorbent assay (ELISA). Octet® BLI systems come ready for good manufacturing practice (GMP) implementation with:
Boost your research and commercialization goals by combining BLI and SPR at an attractive promotional price.
Fc Receptor Binding AssaysThe safety and efficacy of a therapeutic monoclonal antibody can be greatly impacted by its binding to both the target and to the FcγR. Antibodies are often engineered to achieve desired properties, including binding to FcγRs. Octet® BLI systems offer a high throughput and sensitive solution for Fc receptor binding analysis, with a variety of assay-ready biosensor surfaces available for rapid and flexible assay development.
Read Application Note
Reproducible and accurate relative ligand binding potency methods can be used to assess lot-to-lot variability by monitoring either the drug binding response or the kinetics of binding including affinity constants. An ideal method must be stability-indicating as well. The Octet® BLI platform is increasingly used for assessing the potency of drug candidates. Octet® BLI systems:
The active protein concentration can be used to determine the potency of the drug molecule. Octet® instruments can be used to develop methods that measure active protein levels. Traditional protein concentration determination techniques like HPLC are being supplanted by more robust Octet® BLI assays in both upstream and downstream bioprocesses. These assays enable:
This table includes examples of drugs where the Octet® BLI system has been used to generate data submitted as part of the supporting information for the drug’s approval with regulatory bodies.
Drug Name
Target
Drug Modality
Sponsor
Regulatory Agency
Indications
Application
Year ofApproval
Keytruda | Pembrolizumab
PD-1
mAb
Merck
EMA
Non-small cell lung cancer
Affinity Characterization
2015
Tecentriq | Atezolizumab
PD-L1
Roche
Specificity
2017
Comirnaty | BNT162b2
COVID-19
mRNA Vaccine
Pfizer
2020
Ultomiris | Ravulizumab
Human C5
Alexion
Paroxysmal nocturnal hemoglobinuria (PNH)
2019
Livogiva | Teriparatide
PTH
Peptide Biosimilar
Teva
Osteoporosis
Atoltivimab, maftivimab, and odesivimab-ebgn
EBOV glycoprotein
mAb Cocktail
Regeneron
FDA
Ebola virus
Competition studies
Oyavas | Bevacizumab
VEGF-A
mAb Biosimilar
Mabxience
Specificity | Affinity Characterization
2021
Jemperli | Dostarlimab
GSK
Endometrial cancer
Regdanvimab
S protein
Celltrion
Affinity Characterization| Blocking Assay
Xevudy | Sotrovimab
GSK | Vir Biotechnology
Nuvaxovid
Vaccine
Novavax
2022
Kimmtrak | Tebentafusp
CD3 | gp100
TCR
Immunocore
Uveal melanoma (UM)
Tixagevimab | Cilgavimab
mAb Combination
AstraZeneca
Opdualag (nivolumab | relatlimab)
LAG-3 | PD1
BMS
Melanoma
Blocking Assay
A comprehensive tool set for compliance makes the Octet® BLI platform an ideal analytical instrument in regulated environments.
Current regulatory guidelines for assay validation were harmonized for kinetic-based assay to derive a common set of parameters.
This application note discusses and characterizes of the interaction between the SARS-CoV-2 Nucleocapsid (N) protein and human chemokines.
A comprehensive guide for designing and performing assays that accurately measure the binding kinetics of biomolecular interactions and analyte concen...
Whether you're assessing FcRn-Antibody or FcγR-IgG binding interactions, you need a high throughput, versatile, and easy to use solution.
Octet® GxP packages support the GMP compliant implementation, including 21 CFR Part 11 software, validation packages, and biosensor validation support...
Assay design recommendations and best practices for producing the highest quality of kinetic data.
Using Octet® SAX Biosensors
For Process Development and Quality Control
In Lot Release and In-Process Testing of Biologics in GxP Laboratories
Quality control of biological products to support clinical trials and post market assay activities require the evaluation of multiple critical product...
Quantitation assays must show precision, accuracy, linearity, and reproducibility
A method for evaluating the binding of an Fc gamma receptor III (FcγR) molecule to the widely characterized NIST mAb.
Developing Methods for Comparability Studies of Therapeutic Monoclonal Antibodies
Monitors up to 96 biosensors simultaneously, enabling label-free detection for protein quantitation and kinetic characterization at unmatched speed
Ideal for high-throughput applications that demand high sensitivity and low sample volume requirements
Unmatched flexibility and versatility in protein analysis
Get the Latest Updates, Trends and Developments on Label-free, Stress-Free Solutions for Drug Discovery, Biologics Development and Biomanufacturing.
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.